Anglo French Drugs and Industries Unlisted Share Price

The minimum lot is 10 share(s); at the indicative price of about ₹1,075, that is approximately ₹10,750. Indicative reference, not a quote.

As of 16 July 2026, the indicative unlisted share price of Anglo French Drugs and Industries is ₹1,075 per share. This is an over-the-counter reference price, not a stock-exchange quote.

The ISIN of Anglo French Drugs and Industries is INE570E01016. An ISIN is the unique 12-character code that identifies a company's shares in the depository system; this one is verified against NSDL (the National Numbering Agency). You need it to hold or transfer these unlisted shares in your NSDL or CDSL demat account.

Anglo-French Drugs & Industries Limited (AFDIL) is a Bengaluru-based pharmaceutical company incorporated in 1923. It manufactures and markets nutraceutical and therapeutic formulations, including vitamins, protein and food supplements, anti-epileptics, anti-oxidants, sleep-inducing agents, cold and cough preparations, digestive enzymes, calcium supplements, antibiotics, cardiac and anti-inflammatory drugs. It operates through divisions such as AFD Pharma, Hospicare and Optima, and serves both domestic and export markets.

The company is not listed on the NSE or BSE main board. Its shares were historically admitted on the Metropolitan Stock Exchange of India but have not traded there in recent years, so they effectively transact as unlisted shares in the off-market. Unlisted shares are generally bought or sold over the counter through registered intermediaries, with shares transferred in dematerialised form to a buyer's demat account after price and quantity are mutually agreed. This is informational only and not a recommendation to transact.

As an unlisted, off-market security, its indicative price is set by buyer and seller negotiation rather than by a continuous exchange order book. The quoted figure reflects current demand and supply, available free float, the company's reported financials and book value, broader sentiment toward unlisted pharmaceutical names, and any recent corporate disclosures. Because liquidity is limited, the indicative price can move and may differ across sources and dates.

Key reference details include ISIN INE570E01016, CIN L24230KA1923PLC010205, a face value of ₹10 per share, incorporation in 1923, and a registered office in Bengaluru, Karnataka. The company is associated with the Kanoria promoter family and reported revenue of around ₹118 crore for the financial year ending March 2025. These figures are factual reference data and indicative market information, not investment advice.

They can. If the company declares a dividend, unlisted shareholders are eligible like any other shareholder. Many unlisted firms reinvest profits, so dividends are not guaranteed.

After listing, unlisted shares convert into regular listed shares in your demat account and can be traded on the exchange, usually once any applicable SEBI lock-in period ends.

Unlisted shares are less liquid than listed shares. You can sell when a buyer is available through an off-market transfer; there is no continuous exchange market, so exits can take longer.

Unlisted shares carry higher risk and lower liquidity than listed shares, with fewer disclosures and no live market price. This is general information, not investment advice — assess suitability before investing.

An unlisted share price is an indicative, over-the-counter reference set by demand and supply in private deals between buyers and sellers. There is no live exchange quote, so prices can vary across dealers and over time.

Yes. Unlisted shares are delivered in dematerialised form, so you need an active demat account (NSDL or CDSL). No special account type is required — a regular demat account works.

Unlisted shares are sold through an off-market transfer to a buyer via a registered intermediary, settling from your demat account with a contract note. Liquidity depends on buyer availability, so exits can take longer than listed shares.